AKBA Live signals | Maximize Profits with Getagraph.com

BUY 157876 min ago

@ $1.540

Issued: 14 Feb 2024 @ 11:12

Return: -27.27%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -1.28 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases...

Stats
Today's Volume	2.11M
Average Volume	5.10M
Market Cap	234.75M
EPS	$0 ( 2024-05-13 )
Next earnings date	( $-0.0700 ) 2024-08-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.09
ATR14	$0.00700 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-13	Hadas Nicole R.	Sell	12 016	Common Stock
2024-05-13	Dahan Michel	Sell	34 840	Common Stock
2023-08-25	Burke Steven Keith	Sell	27 000	Common Stock
2024-02-29	Dahan Michel	Sell	8 661	Common Stock
2024-02-29	Hadas Nicole R.	Sell	5 974	Common Stock

INSIDER POWER
85.83
Last 97 transactions
Buy: 10 757 338 \| Sell: 785 921

Volume Correlation

Long: -0.21 (neutral)

Short: 0.89 (strong)

Signal:(58.19) Same movement expected

Akebia Therapeutics Inc Correlation

10 Most Positive Correlations
OZEM	1
ENTO	0.809

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Akebia Therapeutics Inc Correlation - Currency/Commodity

0.00
( neutral )

0.22
( neutral )

Akebia Therapeutics Inc Financials

Annual	2023
Revenue:	$194.62M
Gross Profit:	$118.89M (61.09 %)
EPS:	$-0.280

FY	2023
Revenue:	$194.62M
Gross Profit:	$118.89M (61.09 %)
EPS:	$-0.280

FY	2022
Revenue:	$292.60M
Gross Profit:	$207.81M (71.02 %)
EPS:	$-0.580

FY	2021
Revenue:	$213.58M
Gross Profit:	$60.18M (28.18 %)
EPS:	$-1.700

Financial Reports:

No articles found.

Akebia Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.